GlaxoSmithKline PLC (NYSE:GSK) jumped 0.01 points or 0.02% on strong buying and was last priced at $40.94 per share. The shares saw huge fund flow intraday; a massive $16.45 million made their way in through the upticks but an even bigger $17.92 million made their way out through downticks. As per the last observation, the net money flow stood at $(-1.47) million and the up/down ratio was found to be 0.92. The shares have seen a weekly value change of -4.55% .A block trade was recorded in the company shares with a net money flow of $(-2.11) million. The composite value of the funds in upticks was $1.23 million and the total value of funds in downticks was $3.33. As can be seen from the data, the block transaction had the up/down ratio of 0.37.
Currently the company Insiders own 10% of GlaxoSmithKline PLC shares according to the proxy statements. Institutional Investors own 8.38% of GlaxoSmithKline PLC shares.
GlaxoSmithKline PLC (NYSE:GSK) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.1 points or 0.24% at $40.83 with 4,271,732 shares getting traded. Post opening the session at $40.8, the shares hit an intraday low of $40.79 and an intraday high of $41.2171 and the price was in this range throughout the day. The company has a market cap of $99,431 million and the number of outstanding shares have been calculated to be 2,435,250,000 shares. The 52-week high of GlaxoSmithKline PLC (NYSE:GSK) is $45.49 and the 52-week low is $37.24.
GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its human immunodeficiency virus (HIV) business is managed through ViiV Healthcare. GSKs Vaccines has a portfolio of over 30 paediatric, adolescent, adult travel vaccines. GSKs Established Products Portfolio includes over 50 off-patent products, as well as its branded generics business and other local products. The Consumer Healthcare business develops and markets products in four categories, such as wellness, oral health, nutrition and skin health. Its brands include Sensodyne, Panadol, Horlicks, Polident, Paradontax, Tums, ENO, NiQuitin/Nicorette, Abreva, Zovirax and Aquafresh. It operates in the United Kingdom, the United States, Belgium and China.